Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
Autolus Therapeutics plc (Nasdaq: AUTL) has announced its Annual General Meeting (AGM) to be held on June 28, 2022, in London. The official notice for shareholders details the meeting's agenda, which includes ordinary and special resolutions. The company will announce the results of the voting via a press release following the AGM. Autolus is focused on developing advanced T cell therapies for cancer treatment, utilizing proprietary technologies to create targeted therapies aimed at hematological malignancies and solid tumors.
- The AGM provides shareholders a platform to influence company decisions.
- The focus on next-generation T cell therapies positions Autolus in a promising area of oncology.
- The outcomes of the AGM resolutions could lead to uncertain market responses, impacting stock performance.
LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and downloaded from www.autolus.com. The AGM is scheduled to be held at The Studio, WestWorks, White City Place, London W12 7FQ on Tuesday, June 28, 2022, commencing at 8:00 a.m. BST.
The business of the meeting is made up of both ordinary and special resolutions which are regularly submitted to shareholders. The results of the poll votes on the proposed resolutions will be announced, in the usual way, via a press release, as soon as practicable after the conclusion of the AGM.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.
Contact:
Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
When is the Autolus Therapeutics AGM scheduled?
Where will the Autolus AGM take place?
What is the purpose of the Autolus AGM?
How will Autolus share the results of the AGM voting?
What is Autolus Therapeutics focused on?
